Ironlight Markets has partnered with FundBridge Capital to offer the Delta Wellington Ultra Short Treasury On-Chain Fund to eligible accredited investors through a private placement on the Ironlight Portal. FundBridge manages the fund's regulatory and compliance framework, with Wellington Management as sub-advisor handling daily investment management. Libeara provides the tokenization infrastructure enabling on-chain access. This collaboration aims to expand access to institutional-quality tokenized investment opportunities within a regulated environment, reflecting growing interest in digital asset securities.
Ironlight Markets' new fund partnership provides context for financial sector activity on Pluang. As of Oct 13, 2026 22:41 WIB, 52 of 118 Financials-sector US stocks rose while 65 fell. Notable movers include AVAT at USD 1.25 with a -7.75% change, OXLC at USD 8.19 with a -4.77% change, and MARA at USD 9.04 with a -4.24% change.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
